Our Focus

The Colorado Chapter of the National Bleeding Disorders Foundation (NBDF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.

El Capítulo de Colorado de la Fundación Nacional de Trastornos Hemorrágicos (NBDF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento. 


News Articles

 

The National Bleeding Disorders Foundation's (NBDF) impact can be seen across the bleeding disorders community through advocacy, education, research, and programs that support individuals and families with hemophilia, von Willebrand disease, and rare factor disorders at every stage of life. Behind that work is a commitment by the NBDF Board of Directors, a group united by a shared goal of improving the lives of people with bleeding disorders.

Federal: 

Funding for Fiscal Year 2027

CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), provided an update to the bleeding disorders community regarding the availability of the treatment. In a letter to the hemophilia B community, the company stated that they have “reestablished limited supply in April 2026,” and that they remain committed to actively managing the existing supply.

OUR ADVERTISERS


Resource Links

13199 E Montview Blvd
STE 200
Aurora, CO 80045

© National Bleeding Disorders Foundation 2026

Crafted by Firespring